I remember a long-ago @FDAOncology meeting with a small company developing an MDS drug. The company was convinced their drug was synergistic with HMAs & kept saying “we’re 2+2=5.” Finally an FDA official said they were perfectly happy for 2+2 to equal 4, if 4 was safe patients.
New paper:
Most approved drug combinations for advanced cancer (1995-2020) have predictable clinical efficacy, because they have additive effect on Progression-Free Survival times.
In @NatureCancer at https://t.co/Z7xabVpouT
by @HaeunHwangbo@SC_Patterson@PlanaDeborah
1/6
I hope we are moving away from “maximum tolerated dose” in oncology. #MedTwitter
Of the studies I’ve led, the one I am most proud of is the trial that showed that LOWER dose of steroids led to better survival & lower toxicity. @TheLancetOncol#Myeloma https://t.co/LCbAAPST9E
#SACB2022 has been a great meeting with exciting research and fun people in a beautiful location. It's been a pleasure serving on the organizing committee over the last 3+ years
Thrilled (and flattered) to read this preview by one of my scientific heroes and leader in the field of drug #combinationtherapy@ac_palmer @SarahCooperUNC
2 papers out!
1) Across many cancers, the clinical efficacy of combination immunotherapies is predictable from efficacy of their ingredients
https://t.co/WonMZgn6vY
2) Review - what does this mean for precision oncology?
https://t.co/ewU3jdFnWl
1/n
I've developed a model of combination chemotherapy and trained it on DLBCL trials. The ultimate test of my model is to predict new trial results, so I predicted the results of the POLARIX trial. Today I got to check the predictions, and they were right!
https://t.co/wQQYXNDqWh
I'm so excited to share the primary article from my graduate work, published today in @scisignal! I am so proud of this project and thankful for all of my coauthors including @matthewipena and @beveunc.
@CompMedUNC @UNC_BCBP@UNC_PHCO@UNC_SOM
https://t.co/IBOG4gVZHT
Friday meetings with these amazing women to set new goals, celebrate how we crushed last week’s goals, and identify ways we can continue to improve is always the highlight of my week.
Women supporting other women in science is NEVER a bad thing.
Congrats @Aaron_Anselmo on another NIH NOA, this time for a diversity supplement for @UNCBBSP Microbiology and Immunology grad student Jilarie Santos Santiago. Terrific news for such a fantastic student!